Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Osteopore Ltd. ( (AU:OSX) ) has shared an announcement.
Osteopore Ltd. has announced the recruitment of its first patient in a clinical study at Queensland Children’s Hospital, aiming to treat temporal hollowing in children following cranial vault remodelling surgery. The study will explore the use of a 3D-printed, patient-specific scaffold combined with bone marrow aspirate and platelet-rich fibrin to restore the frontotemporal contour. This initiative underscores Osteopore’s commitment to advancing regenerative medicine solutions, particularly for pediatric patients, and positions the company as a leader in innovative medical technology.
More about Osteopore Ltd.
Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia. It specializes in commercializing products that facilitate natural bone healing across various therapeutic areas. The company utilizes patented technology to create micro-structured scaffolds for bone regeneration using 3D printing and bioresorbable materials.
Average Trading Volume: 2,150,114
Technical Sentiment Signal: Sell
Current Market Cap: A$3.52M
Find detailed analytics on OSX stock on TipRanks’ Stock Analysis page.